[1]李蕾,郭艳红,王贵松①,等.超敏C反应蛋白对急诊经皮冠状动脉介入术后患者预后的预测价值[J].中国微创外科杂志,2006,06(7):483-485.
　Li Lei,Guo Yanhong,Wang Guisong,et al.Value of hypersensitive C-reactive protein for predicting the prognosis of patients after em ergent percutaneous coronary intervention[J].Chinese Journal of Minimally Invasive Surgery,2006,06(7):483-485.
点击复制

超敏C反应蛋白对急诊经皮冠状动脉介入术后患者预后的预测价值()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
06
期数:
2006年7期
页码:
483-485
栏目:
出版日期:
2006-07-20

文章信息/Info

Title:
Value of hypersensitive C-reactive protein for predicting the prognosis of patients after em ergent percutaneous coronary intervention
作者:
李蕾; 郭艳红; 王贵松①; 郭丽君; 张福春; 高炜
北京大学第三医院心内科,北京大学心血管研究所,北京,100083
Author(s):
Li Lei;  Guo Yanhong;  Wang Guisong;  et al.
Department of Cardiology, Peking University Third Hospital, Institute of Cardiovascular Research of Peking University, Beijing 100083, China
关键词:
急性心肌梗死; 超敏C反应蛋白; 经皮冠状动脉介入; 主要心脏不良事件
Keywords:
Acutemyocardial infarction; 　Hypersensitive C-reactive protein; 　Percutaneous coronary intervention; 　Major adverse cardiac event
分类号:
R541.4;R446.11+2
文献标志码:
A
摘要:
目的评价超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)对ST段抬高急性心肌梗死(ST elevation myocardial infarction,STEMI)经皮冠状动脉介入(percutaneous coronary intervention,PCI)术后180 d主要心脏不良事件(major adverse cardiac event,MACE)的预测价值. 方法 216例初发STEMI入院时测定hs-CRP,发病12 h内急诊行PCI.根据hs-CRP水平,分为hs-CRP升高组(hs-CRP＞3 mg/L,n=52)和hs-CRP正常组(hs-CRP≤3 mg/L,n=164),随访所有入选患者术后180 d MACE发生率. 结果患者年龄、高血压病史、血脂异常、梗死部位、冠脉病变程度及PCI即刻成功率各组间无明显差异(P>0.05),hs-CRP升高组左心室射血分数低于hs-CRP正常组,WBC和肌酸激酶同工酶峰值显著高于hs-CRP正常组(P<0.05);急诊PCI术后180 d hs-CRP升高组MACE发生率均明显高于hs-CRP正常组(22.0% vs. 9.6%,P＝0.048).多因素分析显示,入院时hs-CRP水平是STEMI患者急诊PCI术后180 d MACE(OR=2.82,95% CI 1.28～5.83,P=0.021)的独立预测因素. 结论入院时hs-CRP升高是STEMI患者急诊PCI术后180 d MACE的相对独立危险因素.
Abstract:
Objective　To evaluate the value of hypersensitive C-reactive protein (hs-CRP) for predicting the incidence of major adverse cardiac events (MACE) in patientswith acutemyocardial infarction (AMI) within 180 days afterpercutaneous coronary intervention (PCI).　M ethods　The study comprised 216 consecutive patientswith first attack ofST-elevationmyocardial infarction (STEMI). They underwentprimaryPCIwithin 12 hours after the onsetofchestpain. According to their serum levels ofhs-CRP, these patientswere divided into two groups: theHigh hs-CRPGroup (>3 mg/L, n=52) and theNormalhs-CRPGroup (≤3 mg/L, n= 164). The incidence ofMACE within 180 postoperative dayswas followed.　Results　There were no significant differences in age, hypertension, hyperlipidemia, left ventricle ejection fraction (LVEF), creatine kinase isoenzyme MB (CK-MB), and immediate success rate ofPCI between the two groups (P<0. 05). TheWBC countwas higher in theHigh hs-CRPGroup than in theNormalhs- CRP Group (P<0. 05). Follow-up for180 days showed theHigh hs-CRP Group had significantly higher incidence ofMACE than the Normalhs-CRPGroup (22. 0% vs 9. 6%,P=0. 048). Binary logistic regression analysis indicated thathigh concentration ofhs-CRP remained an independentpredicator ofMACE within 180 postoperative days (OR=2. 82, 95% CI=1. 28~5. 83,P=0. 021).　 Conclusions　High concentration ofhs-CRP when admission is a useful predictor for the incidence ofMACE in patientswith STEMI within 180 days after primary PCI.

参考文献/References:

[1]Juan CK.Pathophysiology and management of patients with chest pain and normal coronary arteriograms(cardiac syndrome X).Circulation,2004,109:568-572.
[2]Ridker PM,Rifai N,Rose L,et al.Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.N Engl J Med,2002,347:1557-1565.
[3]Albert CM,Ma J,Rifai N,et al.Prospective study of C-reactive protein,homocysteine,and plasma lipid levels as predictors of sudden cardiac death.Circulation,2002,105:2595-2599.
[4]Marrow DA,Rifai N,Antman EM,et al.C-creative protein is a potent predictor of mortality independent of and in combination with troponin T in acute coronary syndromes:a TIMI 11A substudy.J Am Coll Cardiol,1998,31:1460-1465.
[5]Antman EM,Anbe DT,Armstrong PW,et al.2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction.http://www.acc.org/clinical/guidelines/stemi.
[6]Schillinger M,Exner M,STEMIghi J,et al.Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis.Circulation,2003,108:2323-2328.
[7]Rafan N,Riderk PM,Stamper M,et al.Inflammation and risk of cardiaovascular diseases in apparently health men.N End J Med,1997,97:425-428.
[8]Pasceri V,Chang JT,Yeh ET.Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drug.Circulation,2001,103:2531-2534.
[9]Sano T,Tanaka A,Namba M,et al.C-reactive protein and lesion morphology in patients with acute myocardial infarction.Circulation,2003,108:282-285.
[10]Pasceri V,Willerson JT,Yeh ET.Direct proinflammatory effect of C-reactive protein on human endothelial cells.Circulation,2000,102:2165-2168.
[11]Devaraj S,Xu DY,Jialal I.C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells:implications for the metabolic syndrome and atherothrombosis.Circulation,2003,107:398-404.
[12]Verma S,Wang CH,Li SH,et al.A self-fulfilling prophecy:C-reactive protein attenuates nitric oxide production and inhibts angiogenesis.Circulation,2002,106:913-919.

备注/Memo

备注/Memo:
＊基金项目："十五"国家攻关课题,课题编号:2004BA714714B05-01，①通讯作者?
更新日期/Last Update: 2014-02-13